Journal Logo

VIEWPOINTS

Boosting Blood Flow: Intravenous Cyclizine in Microsurgery

Townley, William A. M.R.C.S.; Wright, Ian C. F.R.C.A.; Whitworth, Ian F.R.C.S.(Plast.)

Author Information
Plastic and Reconstructive Surgery: September 2010 - Volume 126 - Issue 3 - p 155e-156e
doi: 10.1097/PRS.0b013e3181e3b51e
  • Free

Sir:

Adequate blood flow across a microvascular anastomosis is a critical factor in maintaining vessel patency and delivering a successful outcome in free flap surgery. Blood pressure is often used as a marker of blood flow intraoperatively because of its relationship with cardiac output (cardiac output = mean arterial pressure/systemic vascular resistance). Anesthetists use several different strategies to increase blood pressure at critical times, such as on completion of an anastomosis or dissection of a vascular pedicle. These include anesthetic modulation, fluid boluses, and sympathomimetics such as ephedrine. Maintaining correct fluid balance intraoperatively is essential; intravenous fluids increase cardiac output but fluid boluses can have an unpredictable effect on blood pressure and may result in undesirable fluid shifts. Intravenous ephedrine may actually decrease cardiac output by increasing systemic vascular resistance.

Cyclizine is an H1-receptor antagonist (antihistamine) that is used primarily as an antiemetic, but in our experience, it is effective at providing a controlled rise in arterial pressure intraoperatively. To illustrate this benefit, we conducted a small prospective study.

Heart rate and arterial blood pressure were assessed in five patients (four men and one woman; mean age, 56 years) undergoing soft-tissue reconstruction. Observations were recorded at 5-minute intervals over a 40-minute period, during which 25 mg of intravenous cyclizine was administered at 10 minutes. Statistical analysis was performed using a paired t test. A value of p < 0.05 was considered statistically significant.

The results are illustrated in Figure 1. Administration of intravenous cyclizine resulted in a mean increase in systolic blood pressure of 9.4 ± 5.4 mmHg at 5 minutes (p = 0.012) over resting pressure, increasing to 18.2 ± 3.5 mmHg at 10 minutes. A significant difference was maintained to 30 minutes after injection. This was mirrored by a significant increase in heart rate (8 ± 5.3 at 5 minutes; p = 0.001), suggesting that cyclizine was mediating changes in blood pressure through a positive chronotropic action. In addition to its favorable physiologic effects, cyclizine benefits from a benign therapeutic profile, although it should be avoided in patients with severe heart failure.1

Fig. 1.
Fig. 1.:
Graph illustrating the change in arterial blood pressure and heart rate following administration of intravenous cyclizine. Asterisks indicate a significant difference between preinjection and postinjection readings (p < 0.05).

Intravenous cyclizine is a safe and effective method of delivering a boost in blood pressure when administered intraoperatively. Although no substitute for judicious fluid management, it is a useful tool for increasing blood flow at critical times during free tissue transfer without the need for sudden volume shifts or vasopressive stimulants.

William A. Townley, M.R.C.S.

Ian C. Wright, F.R.C.A.

Ian Whitworth, F.R.C.S.(Plast.)

Odstock Center for Burns, Plastic and Reconstructive Surgery

Salisbury District Hospital

Salisbury, United Kingdom

DISCLOSURE

There was no financial support for this work, no associated pecuniary or financial interest, and no conflict of interest.

REFERENCE

1.Tan LB, Bryant S, Murray RG. Detrimental haemodynamic effects of cyclizine in heart failure. Lancet. 1988;1:560–561.

Section Description

GUIDELINES

Viewpoints, pertaining to issues of general interest, are welcome, even if they are not related to items previously published. Viewpoints may present unique techniques, brief technology updates, technical notes, and so on. Viewpoints will be published on a space-available basis because they are typically less timesensitive than Letters and other types of articles. Please note the following criteria:

Authors will be listed in the order in which they appear in the submission. Viewpoints should be submitted electronically via PRS' enkwell, at www.editorialmanager.com/prs/. We strongly encourage authors to submit figures in color.

We reserve the right to edit Viewpoints to meet requirements of space and format. Any financial interests relevant to the content must be disclosed. Submission of a Viewpoint constitutes permission for the American Society of Plastic Surgeons and its licensees and assignees to publish it in the Journal and in any other form or medium.

The views, opinions, and conclusions expressed in the Viewpoints represent the personal opinions of the individual writers and not those of the publisher, the Editorial Board, or the sponsors of the Journal. Any stated views, opinions, and conclusions do not reflect the policy of any of the sponsoring organizations or of the institutions with which the writer is affiliated, and the publisher, the Editorial Board, and the sponsoring organizations assume no responsibility for the content of such correspondence.

©2010American Society of Plastic Surgeons